Activation of innate immune mechanisms within the dorsal root ganglion and spinal dorsal horn has been shown to play a key role in the development of neuropathic pain including paclitaxel-related chemotherapy-induced peripheral neuropathy (CIPN). Here, we tested whether similar mechanisms are generalizable to oxaliplatin-induced CIPN. After a single intraperitoneal injection of 3 mg/kg oxaliplatin, mechanical withdrawal threshold and the expression of C-C chemokine ligand 2 (CCL2) and its receptor, CCR2, in the dorsal root ganglion were measured by behavioral testing and immunohistochemical staining, respectively. Mechanical responsiveness increased from the first day after oxaliplatin injection and persisted until day 15, the last day of this experiment. Immunohistochemical showed that the expression of CCL2/CCR2 started to increase by 4 hours after oxaliplatin treatment, was significantly increased at day 4, and then both signals became normalized by day 15. Cotreatment with intrathecal anti-CCL2 antibodies prevented the development of oxaliplatin-induced mechanical hyperresponsiveness, and transiently reversed established hyperalgesia when given 1 week after chemotherapy. This is the first study to demonstrate CCL2/CCR2 signaling in a model of oxaliplatin-related CIPN; and it further shows that blocking of this signal can attenuate the development of oxaliplatininduced mechanical hyperalgesia. Activation of innate immune mechanisms may therefore be a generalized basis for CIPN irrespective of the specific class of agent.
Introduction
Oxaliplatin is a second generation platinum-based chemotherapy drug that is commonly used to treat colorectal cancer. 42 Like many other anticancer agents, chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of oxaliplatin treatment and is the main dose-limiting toxicity of this drug. 5 Up to 90% of all cancer patients treated with chemotherapy are estimated to develop CIPN, minimally manifested as numbness and tingling but at the extreme resulting in spontaneous burning pain. 30 Many oxaliplatin-treated patients also experience acute, transient sensory disturbances expressed as cold-triggered paresthesia of the distal extremities. Over 60% of patients completing oxaliplatin chemotherapy complain of persistent neuropathy with chronic pain occurring in 20% to 54% of patients 2, 5, 38, 54 that can last for months after treatment cessation 1, 13, 63 negatively impacting quality of life. 40, 53 Despite recent progress, the mechanism of CIPN is not fully defined; and this has hindered the implementation of fully effective treatment strategies for its relief or prevention.
One mechanism contributing to the generation of CIPN produced by another agent, paclitaxel, is the activation of innate immune mechanisms in the dorsal root ganglion (DRG) and spinal dorsal horn. 4, 31, 64 Paclitaxel increases the signaling of Toll-like receptor 4 (TLR4) in DRG neurons, 34, 35 which leads to increased expression of C-C chemokine ligand 2 (CCL2), also called monocyte chemotactic protein 1 (MCP-1). 65 CCL2 and its receptor, C-C chemokine receptor 2 (CCR2), are key players in the attraction of monocytes to sites of injury and inflammation. 3, 58 CCL2 increases the excitability of neurons in chronically compressed DRG, an injury that is also associated with an overexpression of neuronal CCL2 and CCR2. 50, 59 CCL2 was shown to recruit macrophage infiltration to the DRG that was critical in the induction of behavioral signs and reduction in distal epidermal nerve fiber (ENF) density after paclitaxel treatment. 67 The clinical phenotype of CIPN including the reported symptoms, their distribution, the change in quantitative sensory function, and the loss of ENFs is remarkably constant, regardless of the provoking agent. 9, 10, 18 Similarly, the preclinical models of paclitaxel and oxaliplatin CIPN share the same pattern of spinal astrocyte activation 47, 68 ; and, cotreatment with a nonspecific inhibitor of innate immunity, minocycline, prevents both paclitaxel-and oxaliplatin-induced mechanical hypersensitivity and ENF loss. 7, 8 This leads to the hypothesis that CIPN regardless of the provoking agent shares at least some underlying mechanisms. As a first test of this important unifying hypothesis for CIPN, the goal of this work was to test generalizability of a role for CCL2/CCR2 signaling within the DRG in the development of oxaliplatin-related CIPN. The development of oxaliplatin-induced mechanical hypersensitivity was assessed by behavior testing, and changes in CCL2/CCR2 expression in DRG neurons were tested using immunohistochemistry (IHC). The expectation was that increased expression of CCL2/CCR2 would accompany mechanical hypersensitivity. Mechanistic linkage between these observations was tested using intrathecal anti-CCL2 antibodies concurrently with oxaliplatin and also after oxaliplatin treatment. Our data show that CCL2/CCR2 in the DRG could be potential targets for the treatment of CIPN.
Methods

Subjects
Sixty-three adult male Sprague-Dawley rats (8-12 weeks old) were used in the study. All animals were housed in a 12-hour light/ dark cycle (7A-7P) with free access to food and water. The procedures were approved by the Institutional Animal Care and Use Committee at The University of Texas MD Anderson Cancer Center and were performed according to the guidelines stated by the National Institutes of Health for Use and Care of Laboratory Animals (NIH publications number 80-23) revised in 2011 and by the committee of research and ethical issues of the International Association for the Study of Pain. 72 
Anesthesia
Animals were anesthetized with isoflurane (Isothesia, 2.5%-3%, inhalation; Piramal Enterprises, Andhra Pradesh, India) before intrathecal injections. Then, before being killed for immunohistochemistry studies, they were deeply anesthetized with sodium pentobarbital (Nembutal, 100 mg/kg, intraperitoneal; Lundbeck Inc, Deerfield, IL).
Drug administration
Oxaliplatin (Tocris) was dissolved in saline to a concentration of 1 mg/mL. After all baseline responses were measured (day 0), rats were randomly selected to receive a single intraperitoneal injection of oxaliplatin (3 mg/kg) or an equivalent volume of saline vehicle (day 1). Intrathecal injections of anti-CCL2 antibodies were used to test mechanistic linkage between behavioral change induced by oxaliplatin and increased expression of CCL2 using methods previously described. 65 Briefly, 10 mL anti-CCL2 immunoglobulin G (IgG) (500 mg/mL; R&D, Minneapolis, MN) or nonspecific IgG (NS-IgG) was injected in the L5-L6 intervertebral space. Intrathecal drugs were delivered using a 0.5-inch 30-gauge needle connected to a Luer-tipped Hamilton syringe. Accurate positioning of the needle inside the subarachnoid space was verified by the occurrence of a brisk tail flick on introduction. Rats were randomly divided into 4 groups that were used in 2 protocols according to the timing of intrathecal injections. The first 2 groups were used to test the effect of blocking CCL2 in preventing the development of oxaliplatinrelated CIPN. One group of rats received 4 daily doses of anti-CCL2 antibodies and a second group received nonspecific Ig starting 2 days before treatment and continuing to day 2 after treatment with oxaliplatin. On the day where both injections were made (day 1), the intrathecal injections were given 1 hour before oxaliplatin. The remaining 2 groups were used to test for reversal of established CIPN-related mechanical hypersensitivity. Rats with confirmed mechanical hypersensitivity (methods appear in the next section) received 4 daily doses of the antibody (group 3) or nonspecific Ig (group 4) beginning 1 week after oxaliplatin treatment (days 7-10). All injections were performed by an investigator blinded to treatment conditions. Animals were observed for any adverse side effects for 2 hours after all injections without occurrence.
Behavioral testing
Mechanical sensitivity was assessed using the "up-and-down" method as previously described 17 and used by us in several previous studies. 35, 65, 67 All behavior testing was conducted by an investigator blinded to treatment conditions. Environmental factors (ie, noise level, lighting conditions, and time of testing) were held constant throughout all experiments. Testing was performed in the morning hours (8:00-11:00 AM). Animals were placed beneath Plexiglas containers (10 3 10 3 4 inches) set on elevated wire mesh stands and allowed to acclimate for 15 minutes. The 50% withdrawal threshold was determined using a series of 8 von Frey monofilaments (0.41, 0.70, 1.20, 2.00, 3.63, 5.50, 8.50, and 15.10 g). Beginning with a bending force of 2.0 g, monofilaments were applied with a force sufficient enough to cause a slight bending against the plantar surface and held for 6 to 8 seconds without any acceleration in the bending force. Flinching or licking after sharply withdrawing the paw was considered a positive response. Uncertain movement was not counted, and the testing was repeated after allowing the animal to rest from the previous stimuli for at least 1 minute. A positive response was followed by another stimulation 1 minute later with the next lower force filament. If no response was seen, stimulation with the next higher force monofilament was applied 1 minute apart from the previous until 3 responses for the same filament were obtained.
Immunohistochemistry
Animals were deeply anesthetized and then perfused through the ascending aorta with warm saline followed by cold 4% Zamboni fixative in 0.1 M phosphate buffer. The L4 and 5 DRG were removed and postfixed in 4% Zamboni fixative overnight and then cryoprotected in 30% sucrose solution at 4˚C. Longitudinal (20 mm) sections were cut in a cryostat and washed with phosphatebuffered saline 3 times for 10 minutes. The slices were blocked in 5% normal donkey serum and 0.2% Triton X-100 in phosphatebuffered saline at room temperature for 30 minutes. Dorsal root ganglion sections were incubated overnight at 4˚C in 1% normal donkey serum containing primary antibodies to determine the cellular colocalization of CCL2 and CCR2 to DRG neuron subtypes: anti-CCL2 (rabbit, 1:500; Millipore, Temecula, CA), anti-CCR2 (goat, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA), anti-calcitonin gene-related peptide (CGRP) (guinea pig, 1: 2000; Peninsula Labs, San Carlos, CA), anti-Bandeiraea (griffonia) simplicifolia I-isolectin B4 (IB4) (L2895; Sigma-Aldrich; St. Louis, MO), and anti-transient receptor potential cation channel vanalloid 1 (TRPV1) (goat, 1:1000; Neuromics, Edina, MN). On the second day, slices were washed 3 times for 10 minutes and then incubated with Cy-3 or fluorescein isothiocyanateconjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) overnight at 4˚C. Negative controls for all experiments entailed omission of the primary antibodies. Sections were washed and then mounted on glass slides and viewed under a fluorescent microscope (Eclipse E600; Nikon, Tokyo, Japan). Immunohistochemical images of the DRG were captured using a 203 objective and constant acquisition parameters by investigators blinded to treatment conditions.
Quantification
Five slices were examined for each animal. All counting was performed using NIC Elements Imaging Software (Nikon) by an experimenter blinded to all treatment conditions. The number of CCL2 and CCR2 positively stained neurons along with their diameters was defined. The intensity of positively stained cells was at least 4 times higher than the background by setting a threshold according to each individual slice. Diamidino-2-phenylindole nucleic acid staining was used to count the total number of neurons in the same slice.
Statistical analysis
Data for 50% withdrawal threshold and counts of CCL2-and CCR2-positive cells are presented as mean 6 SEM. The differences between mean were analyzed using the MannWhitney U test (IHC) or 2-way analysis of variance (ANOVA, behavior) followed by the Bonferroni post hoc test. A value of P , 0.05 was considered statistically significant.
Results
Mechanical hypersensitivity was induced by single-dose oxaliplatin treatment
Mechanical hypersensitivity was evidenced by a reduction in the 50% withdrawal threshold over several time points (Fig. 1) . Oxaliplatin-treated rats (n 5 7) exhibited decreased mechanical withdrawal threshold in comparison with vehicle (saline)-treated rats (n 5 8). The decrease from baseline started on day 2 (24 hours after oxaliplatin injection) where vehicle-treated rats showed a 50% withdrawal threshold of 8.9 6 1.6 g and oxaliplatin-treated rats dropped to 4.2 6 1.1 g (P , 0.001, Mann-Whitney U test). Oxaliplatin-induced mechanical hypersensitivity was sustained through the end of the observation period (day 15) where vehicle-treated rats showed 50% withdrawal threshold of 9.6 6 1.7 g, whereas in oxaliplatin rats, it was 5.9 6 1.4 g (P , 0.001).
Single-dose oxaliplatin induced an increase in expression of CCL2 in small dorsal root ganglion neurons
The expression of CCL2 in the DRG was quantified with IHC ( Figs. 2A and B) . Oxaliplatin-treated rats showed a trend to increased expression of CCL2 as early as 4 hours after treatment compared with vehicle rats. Oxaliplatin-treated rats (n 5 4) showed 8.3% of DRG neurons to be positively stained for CCL2 (207/2490 total), whereas vehicle-treated animals (n 5 4) showed 5.4% of cells to be CCL2 positive (138/2535 total). On day 4, the expression of CCL2 was significantly higher in oxaliplatin-treated rats (n 5 3), 10.9% of DRG neurons were positive for CCL2 (217/ 1996 total), whereas in saline-treated rats (n 5 4), only 3.1% of DRG neurons were positive for CCL2 (115/3736 total; P , 0.001, 2-way ANOVA). These differences were no longer present by day 15 after treatment, as the expression of CCL2 in oxaliplatintreated rats (N 5 6) was found in 4.5% of the DRG neurons (185/ 4114 total), whereas in saline-treated rats (N 5 6), 3.3% of DRG neurons were CCL2 positive (151/4597 total).
The majority of CCL2 was expressed by small (#30 mm) DRG neurons (Fig. 2C) . Colocalization further identified these small neurons as nociceptors, given that CCL2 was found in cell profiles positive for the nociceptor-specific markers IB4 and CGRP (Fig. 2D) . For oxaliplatin-treated rats, 4 hours after injection, 85.5% of CCL2-positive neurons were small cells, 13.8% were medium-sized cells (31-44 mm), and only 0.7% were large cells ($45 mm). At day 4 after oxaliplatin, 90.3% of CCL2-positive neurons were small cells and 9.7% were medium-sized cells with no large cells stained positively for CCL2. Finally, on day 15, 86.5% of CCL2-positive neurons were small cells, 13.5% were medium-sized cells, and there were still no CCL2-positive large cells seen at this time point.
Upregulation of CCR2-positive cells in the dorsal root ganglion after single dose of oxaliplatin
The expression of CCR2 in the DRG after oxaliplatin treatment was measured and quantified in the same fashion as that for CCL2 described above. As shown in Figure 3B , after a single injection with oxaliplatin or saline, there was no significant difference in the number of CCR2-positive cells between the 2 groups at 4 hours after injection (n 5 4 for each group) nor on day 15 (n 5 6 for each group). In oxaliplatin-treated rats, 4.5% (74/ 1645 total) and 14.0% (219/1565 total) of DRG neurons were positive for CCR-2 at 4 hours after the injection and on day 15, respectively. These results were very close to the vehicle group that had 3.0% (47/1585 total) of neurons stained positively for CCR-2 after 4 hours and 13.9% on day 15 (238/1709). However, the number of CCR2-positive neurons was significantly increased at day 4 after oxaliplatin treatment where 28.9% (269/930 total) of DRG neurons were positively stained for CCR2 in oxaliplatintreated rats (n 5 3) compared with 13.9% (142/1021) of neurons in vehicle-treated rats (n 5 4) (P , 0.05, 2-way ANOVA).
As in our previous study in paclitaxel CIPN, 65 CCR2 was mainly observed in large and medium-sized DRG cells (Fig.  3C) . Nevertheless, colocalization was found also in some TRPV1-positive neurons (Fig. 3D) . After 2 hours of single-dose oxaliplatin injection, 21.6% of CCR2-positive neurons were large cells ($45 mm), 74.3% were medium-sized cells (30-45 mm), and only 4.1% of CCR2-positive neurons were small cells (#30 mm). At 4 days after oxaliplatin treatment, the percentage of CCR2-positive neurons was 50.2% large cells, 42.4% medium-sized cells, and 7.4% small cells. Last, on day 15 after oxaliplatin injection, 44.3% of large cells, 35.6% of mediumsized cells, and 20.2% of the small cells were CCR2 positive. Therefore, CCR2 was expressed in both large diameter presumably nonnociceptive DRG neurons as well as medium-sized neurons likely to be Ad nociceptors but in few small DRG neurons that were likely C-nociceptors. 
Intrathecal anti-CCL2 given before and during oxaliplatin treatment attenuated the development of mechanical allodynia
Intrathecal injection of anti-CCL2 antibodies produced no change in response to von Frey stimulation from the baseline behavioral tests collected before initiating chemotherapy treatment (Fig. 4) . Furthermore, there was no significant difference between the 50% withdrawal threshold of intrathecal anti-CCL2-treated rats (12.8 6 1.4 g, n 5 4) and those that received intrathecal NS-IgG (13.0 6 1.3 g, n 5 4) on day 0. However, the 50% withdrawal threshold of NS-IgG 1 oxaliplatin-treated rats dropped significantly from this baseline at days 2, 4, 6, 8, and 15, respectively. By contrast, the mechanical withdrawal threshold for the anti-CCL2 1 oxaliplatin-treated rats remained near the baseline values at each measurement time point. Threshold values of anti-CCL2-treated rats were significantly higher than the values in rats treated with NS-IgG specifically on days 6, 8, and 15 (P , 0.01). Hence, intrathecal anti-CCL2 reduced the development of oxaliplatin-induced mechanical hypersensitivity.
Intrathecal anti-CCL2 antibodies transiently reverse preestablished oxaliplatin-induced mechanical allodynia
Both groups of rats showed mechanical hypersensitivity when assessed at day 7 after oxaliplatin ( Fig. 5) . Rats treated with NSIgG (n 5 6) showed no improvement in 50% withdrawal threshold over the course of the experiment. On the other hand, treatment with intrathecal anti-CCL2 IgG (n 5 7) raised the 50% withdrawal threshold value from 1.78 6 0.2 g before treatment on day 7 to 8.4 6 1.8 g the next day, after 2 doses of anti-CCL2 on day 8. Mechanical withdrawal threshold showed further improvement with continued anti-CCL2 antibody treatment on days 9 and 10 (P , 0.001, 2-way ANOVA). The effect faded quickly on discontinuation of anti-CCL2 antibody treatment such that there was no significant difference between the 2 groups across days 11 to 16.
Discussion
The main findings in this study are that CCL2 and its receptor CCR2 are increased in the DRG after oxaliplatin treatment in parallel to the development of mechanical hypersensitivity. In addition, intrathecal treatment with an anti-CCL2 antibody during oxaliplatin administration prevents the development of mechanical hypersensitivity; and intrathecal anti-CCL2 antibody treatment also transiently reverses preestablished oxaliplatin-induced mechanical hypersensitivity. These data seem to confirm that there is a generalizability of mechanisms across models of CIPN produced using chemotherapy drugs with very different anticancer actions and seem to implicate effects of the innate immune response in these mechanisms. Models of CIPN using intraperitoneal injection of oxaliplatin have been widely studied. 16, 26, 27 Here, a single injection of 3 mg/kg oxaliplatin-induced mechanical hypersensitivity that lasted to 15 days after treatment. This finding is similar though differing in duration from a previous study using a similar singledose approach where mechanical hyperresponsiveness recovered at day 10 after treatment. 36 This difference is most likely due to the different techniques for assessment of mechanical responsiveness. Here, we simply followed the up-down method as established by Chaplan et al., 17 whereas the other study 36 assessed mechanical responsiveness using the method of Tal and Bennett. 51 These 2 methods differ in the force, frequency, and duration that the stimuli are applied. In Tal and Bennet method, greater diameter von Frey monofilaments (1.479, 2.041, 3.63, 5.495, 8.511, 11.749, 15.136, and 28.84 g) were used with a series of 5 stimuli for each monofilament applied for 3 to 5 seconds. The threshold was then determined as the lowest force that evoked a withdrawal response to 1 of the 5 stimuli. In contrast, Chaplan's method uses of a series of smaller diameter monofilaments (0.41, 0.70, 1.20, 2.00, 3.63, 5.50, 8.50, and 15.10 g) applied for 6-8 s each and the 50% withdrawal threshold is determined using the method of Dixon.
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A strong rationale for studying the effects of a single dose of oxaliplatin on DRG neurons as performed here and previously 36 is that the symptoms experienced early in oxaliplatin chemotherapy by patients are strong predictors of long-term CIPN outcomes. 44 Oxaliplatin-related symptoms persisted between dosing cycles and built in intensity with repeated treatment, 44 suggesting that the innate immune mechanisms in the DRG revealed here as engaged by oxaliplatin in animals would similarly be expected to become more exaggerated with repeated dosing. Yet, a clear limitation in the single-dose models is that rats only received roughly one-fifth the amount of oxaliplatin that would normally be given to patients. Previous experience with platin-based chemotherapy agents showed that higher doses produced a loss of withdrawal response possibly indicative of the development of numbness.
14 Although patients also develop numbness, this level of neuropathy in rats presents potential difficulty in the interpretation of experimental results and so the lower doses were used as typical in experimental models of both platin-and taxaneinduced CIPN. 7, 8, 45, 61 Thus, in considering translation of these findings to the clinic, patients might have more exaggerated innate immune responses than seen here that might require more prolonged or higher dose administration of CCR2 antagonists, by example, to suppress the development of CIPN.
Acute dysesthesia after oxaliplatin infusion occurs in over 70% of patients. 46, 49 Symptoms were reported during or immediately after the infusion and would last for a few minute to several days and in most cases, these symptoms were dose related. 22, 24, 25 The emergence of CIPN symptoms is often the main reason for poor compliance in patients receiving chemotherapy, forcing dose reduction, and leading to suboptimal therapy. 1, 16 Although the mechanism of CIPN is still unclear, many possible pathways have been suggested. 11, 12, 30, 55 Genetic predispositions have been implicated 6, 15, 60 ; and in a recent clinical study, 57 subthreshold neuropathy evidenced by deficits in fine touch detection have also been implicated. Other mechanisms such as expression of inflammatory mediators including cytokines and chemokines, 4, 31, 64 DNA damage, 39 alterations in ion channels and neurotransmission, 41, 48 and altered intracellular signaling and cellular function, particularly in mitochondria 21, 62, 70, 71 have all been implicated in the development of CIPN.
Work in our laboratory has focused on the role of the innate and adaptive immune system in producing CIPN. CCL2/CCR2 signaling between myelinated and unmyelinated neurons of the DRG was suggested to contribute to paclitaxel-induced mechanical hypersensitivity. 65 In this study, overexpression of CCL2 in DRG was seen 4 hs after a single dose of oxaliplatin, followed by a significant increase in CCR2 on day 4 and this parallels the increase in onset of mechanical hypersensitivity. Cotreatment of rats with CCL2-neutralizing antibodies resulted in an attenuated level of behavioral hypersensitivity, suggesting a mechanistic linkage between the behavioral changes and increased CCL2 expression. Yet, of note, the cotreatment was not complete, indicating that some of the other mechanisms implicated in CIPN as reviewed above had possibly still been engaged. However, on day 15, the levels of CCL2/CCR2 had decreased to that seen in vehicle-treated rats, whereas the mechanical hypersensitivity was still apparent. This would seem to suggest that CCL2/CCR2 signaling participates in the onset of oxaliplatin CIPN, but that other mediators become engaged at later stages of the model to maintain behavioral hypersensitivity. Yet, CCL2 antibody treatment showed an attenuation of preestablished mechanical hypersensitivity, suggesting that despite the reduced expression level, CCL2/CCR continues to play a key role in maintaining oxaliplatin CIPN. It would seem that either the signaling of CCR2 is sensitized at these later time points, or there is a non-DRG neuron source of CCL2 that becomes engaged at this later time point. As in our previous study with paclitaxel CIPN, oxaliplatininduced increases in CCL2 was found primarily in small CGRP and IB4-positive DRG neurons, whereas its receptor CCR2 was primarily expressed in medium and large DRG neurons. This implies that both myelinated Ab and Ad neurons as well as unmyelinated C neurons in the DRG are involved in oxaliplatininduced sensory dysfunction. 29, 32, 56 This would be consistent with the findings that ectopic spontaneous activity (SA) develops in all 3 cell types with paclitaxel chemotherapy. 33, 66 Spontaneous activity in large and medium-sized DRG neurons was assayed using a whole DRG explant preparation where factors from neighboring cells were preserved; and CCL2 was shown to evoke calcium influx in both cell types, 66 thus CCL2 may be a primary driving factor for altered function in these neurons. As well, SA and altered signaling in large DRG neurons is consistent with numerous reports for a role of these DRG neuron types in contributing to neuropathic pain. 19, 37 Small DRG neurons show SA in dissociated cultures and so, CCL2 is unlikely to drive altered activity in these cells. 33 The question could be asked as to whether CCL2/CCR2 signaling in the spinal cord might contribute to oxaliplatinrelated CIPN. Although a role for increased CCL2/CCR2 expression and presumably its signaling are well documented in the DRG, 28, 52, 65, 69 the expression of CCR2 in the spinal cord is debated. 23, 43 We did not detect CCR2 protein or mRNA in the spinal dorsal horn after paclitaxel treatment in our previous study 65 ; and so, we concluded that the major site of action of CCL2 in paclitaxel CIPN is within the DRG rather than in the spinal cord. Nevertheless, a role for CCL2/ CCR2 in the spinal cord in oxaliplatin-related CIPN cannot be excluded.
In conclusion, induction of CCL2/CCR2 signaling in DRG after single-dose oxaliplatin contributes to increased mechanical allodynia and blocking this signal could be useful both as prophylaxis against neuropathy and as a salvage measure in patients previously treated with oxaliplatin.
